Cassava Sciences stock (US14428V1035): pressure grows as short interest stays elevated after ticker change to FLNA

Cassava Sciences has changed its Nasdaq ticker to FLNA while the share price trades near multi?year lows and short interest remains high. What is behind the latest moves and how does the Alzheimer’s developer make its money?

Cassava Sciences stock is trading near its lowest levels in years just weeks after the company’s Nasdaq ticker switched from SAVA to FLNA, while short interest remains elevated at almost 15% of free float, according to recent data from MarketBeat as of April 30, 2026 and Robinhood’s corporate actions tracker as of May 2026. These developments keep the Alzheimer’s drug developer in focus for both speculative traders and long?term biotech investors, even though the underlying business remains in a clinical stage with no approved products yet.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Cassava Sciences, Inc.
• Sector/industry: Biotechnology, neurology
• Headquarters/country: Austin, Texas, USA
• Core markets: Alzheimer’s disease research and development
• Key revenue drivers: R&D funding, potential future drug sales
• Home exchange/listing venue: Nasdaq (ticker: FLNA)
• Trading currency: USD

Cassava Sciences: current market situation and ticker change

The company’s shares now trade under the Nasdaq symbol FLNA after a recent corporate action in 2026, replacing the former ticker SAVA, according to Robinhood’s corporate actions overview published in May 2026, which notes that Cassava Sciences performed a ticker change to FLNA alongside other actions in the sector.Robinhood corporate actions tracker as of 05/2026

The stock was quoted at about 1.18–1.19 USD at the latest close on Nasdaq, implying a market valuation of roughly 57 million USD, and has lost more than 40% over the past 12 months and almost 32% over the last month, highlighting persistent selling pressure in 2026, according toMarketBeat chart data as of 05/2026.

Over a five?year horizon, Cassava Sciences has seen its share price decline by more than 90% from a split?adjusted level above 30 USD, underscoring the dramatic shift in investor sentiment since earlier hype around its experimental Alzheimer’s therapy, based on the same MarketBeat performance overview as of May 2026.

Short?selling activity remains a key feature of the trading profile: short interest totaled around 6.85 million shares as of April 30, 2026, corresponding to approximately 14.86% of the public float, and declined only modestly by about 1.1% compared with the previous reporting date, according toMarketBeat short?interest data as of 04/30/2026.

The combination of a very low share price, modest market capitalization and high short interest can translate into elevated volatility for day?to?day trading, with incremental company news or regulatory headlines potentially moving the stock disproportionately compared with larger, diversified biotech peers.

Cassava Sciences: core business model

Cassava Sciences is a US biotech company focused on developing treatments for Alzheimer’s disease, one of the largest unmet medical needs in neurology. The business model is typical for clinical?stage biotechnology players: the company currently generates negligible product revenue and primarily invests in research and development with the goal of achieving regulatory approval and commercializing its lead drug candidate in the future, based on company descriptions in its investor materials and filings available in 2025 and 2026.

Its principal asset is an oral small?molecule drug candidate for Alzheimer’s disease that has been studied in mid? to late?stage clinical trials. Earlier company communications described late?stage studies in patients with mild?to?moderate Alzheimer’s, with the aim of slowing cognitive decline and improving daily functioning, according to summaries found in Cassava’s prior investor presentations and regulatory filings published before 2026.

As is common for this type of biotech, Cassava Sciences finances its operations via equity issuance and potentially other capital markets instruments rather than from product sales. This means dilution risk and financing conditions on Nasdaq are central to the company’s long?term viability while it works through lengthy clinical programs.

Given that the company is headquartered in Austin, Texas, and listed in New York, its core investor base and many research partners are located in the US. For US?based investors, Cassava Sciences sits within a crowded but strategically important segment of the market: developers targeting neurodegenerative diseases, where several large?cap pharma and biotech groups have recently gained or sought approval for Alzheimer’s therapies.

Main revenue and product drivers for Cassava Sciences

As of mid?2026, Cassava Sciences does not yet commercialize an approved drug and thus does not rely on recurring product revenue. Instead, its future revenue potential is tied largely to the clinical and regulatory success of its Alzheimer’s candidate. If clinical trials meet primary endpoints and regulators ultimately grant approval, the company could seek to generate income through direct drug sales, partnerships, or licensing agreements, according to standard biotech commercialization models seen in the US market.

The main operational driver today is spending on research and development, including clinical trial costs, manufacturing of study drug, and medical monitoring. These expenses determine the company’s cash burn rate and therefore the timing and size of any future capital raises. Investors typically monitor quarterly financial reports to track R&D spending and cash on hand, metrics that Cassava Sciences has regularly disclosed in SEC filings over previous reporting periods.

Beyond its flagship Alzheimer’s program, Cassava Sciences has historically explored earlier?stage assets and research initiatives that might one day broaden the pipeline. However, the Alzheimer’s candidate remains the dominant value driver, meaning trial outcomes, safety updates and interactions with regulators represent key catalysts for the stock in coming years.

The company’s ability to secure strategic collaborations with larger pharmaceutical companies could also influence long?term revenue prospects. For many clinical?stage biotechs in the US, partnering deals can provide non?dilutive funding via milestones and royalties, while giving access to established commercial infrastructures once a therapy reaches the market.

Conclusion

Cassava Sciences finds itself in a challenging position: the share price has fallen sharply over multi?year horizons and now trades close to the 1 USD mark even after a recent ticker change to FLNA, while short interest remains high relative to floating shares.MarketBeat short?interest overview as of 04/30/2026Yet, the company continues to pursue its Alzheimer’s candidate within a field that is strategically important for the US healthcare system and global aging populations. For investors, Cassava Sciences represents a high?risk, event?driven biotech story where progress in clinical trials, financing steps and regulatory developments are likely to drive sentiment more than traditional valuation metrics in the near term.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.